Yousif Capital Management 13F: New $806K Stake in ARQT

Yousif Capital Management opened a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), acquiring 30,489 shares valued at about $805,824. The fund disclosed the new holdings in a Form 13F filing with the SEC on October 22, 2026. Arcutis shares closed at $32.20 on the day of the filing.

ARQT Arcutis Biotherapeutics, Inc.

$31.20 ▲ +7.59% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Yousif Capital Management's Arcutis Biotherapeutics, Inc. Position

Yousif Capital Management initiated a brand-new stake in Arcutis Biotherapeutics, Inc. during the period, purchasing 30,489 shares. The reported value of the new holding stood at $805,824 based on the quarterly data.

Other Institutional Activity in Arcutis Biotherapeutics, Inc.

Other large investors adjusted their holdings in the biotech company around the same timeframe. Marshall Wace grew its holdings by 1,977,545 shares, ending with 2,431,778 shares worth about $63.76 million. Montanova Capital LLC added 109,713 shares for a total of 12,437,000 shares valued at $388.03 million. Frazier Life Sciences Management, L.P. held steady with 9,874,511 shares worth $308.08 million. Rubric Capital Management LP kept its stake unchanged at 8,271,577 shares valued at $258.07 million. Polar Capital Holdings PLC raised its position by 940,125 shares, bringing its total to 6,606,945 shares worth $206.14 million.

Arcutis Biotherapeutics, Inc. Stock Down 2.1%

The stock recently traded around $31.20 as of October 24, 2026, down about 3.1% from its filing-day close of $32.20. The shares trade well above their 50-day moving average of $25.98 and sit comfortably higher than their 52-week low of $19.30.

Recent Earnings

Arcutis Biotherapeutics, Inc. reported trailing twelve month revenue of $463.98 million and basic earnings per share of $0.22. The firm achieved a net profit margin of 6.1% and a return on equity of 15.9%. Investors await the next financial update scheduled for November 4, 2026.

Insider Buying and Selling at Arcutis Biotherapeutics, Inc.

Insiders completed several transactions recently. Officer Masaru Matsuda sold 9,989 shares on September 8, 2026, at an average price of $25.03 for a total value of $249,986. Director Howard G. Welgus sold 4,730 shares on September 15, 2026, at $24.18 per share totaling $114,371. Welgus also sold 4,728 shares on October 15, 2026, at $26.93 per share in a planned trade.

Analysts Set New Price Targets

Wall Street firms updated their outlooks ahead of the filing. Morgan Stanley maintained an Overweight rating with a target of $38.00 on August 6, 2026. Guggenheim kept a Buy rating on August 6, 2026, lifting its target to $38.00, and later maintained a Buy rating on October 19, 2026, raising its target to $44.00. Needham kept a Buy rating on August 6, 2026, with a target of $40.00. Cantor Fitzgerald initiated coverage with an Overweight rating and a $48.00 target on October 15, 2026.

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on creating treatments for dermatological conditions. Its flagship product, ZORYVE, is a topical cream utilized for plaque psoriasis and atopic dermatitis. The firm also develops other topical foam treatments for seborrheic dermatitis along with various protein candidates targeting autoimmune and skin disorders.

Bottom Line

Market participants will monitor the upcoming earnings release on November 4, 2026, for further updates on commercial progress for ZORYVE. Future regulatory filings will reveal whether institutional buyers like Yousif Capital Management maintain or grow their exposure to the stock.